financetom
Business
financetom
/
Business
/
Quantum Computing Stocks Rise After Microsoft Says 2025 is Year to Get 'Quantum Ready'
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Quantum Computing Stocks Rise After Microsoft Says 2025 is Year to Get 'Quantum Ready'
Jan 15, 2025 7:58 AM

10:22 AM EST, 01/15/2025 (MT Newswires) -- Quantum computing stocks were rising in recent Wednesday trading after a Microsoft (MSFT) blog post said 2025 is the year to get "quantum ready."

Rigetti Computing ( RGTI ) shares were recently up more than 20%; D-Wave Quantum ( QBTS ) surged 22%, and IONQ ( IONQ ) gained more than 21%.

"As we look toward the next 12 months, the pace of quantum research and development is only going to accelerate, making this a critical and catalyzing time for business leaders to act," Mitra Azizirad, president and chief operating officer of strategic missions and technologies at Microsoft, said in a blog post Tuesday.

Azizirad also said that Microsoft is launching a "Quantum Ready program" to help companies address challenges in the quantum-computing space.

Separately, Nvidia (NVDA) said Tuesday that it will have a "Quantum Day" on March 20 at its GTC 2025 conference. The company said Nvidia Chief Executive Jensen Huang will "host industry leaders to discuss where quantum computing is headed."

Price: 10.81, Change: +1.86, Percent Change: +20.79

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cabaletta Bio Gets Orphan Drug Designation From FDA For Systemic Sclerosis Treatment
Cabaletta Bio Gets Orphan Drug Designation From FDA For Systemic Sclerosis Treatment
Mar 20, 2024
10:57 AM EDT, 03/20/2024 (MT Newswires) -- Cabaletta Bio ( CABA ) said Wednesday the US Food and Drug Administration has given orphan drug designation to CABA-201 to potentially treat systemic sclerosis. The candidate drug is being developed to treat autoimmune diseases driven by B cells, the company said, adding the clinical trial program has four phase 1/2 trials to...
New Fortress Energy Closes on Purchase of Electricity Supply Contract in Brazil
New Fortress Energy Closes on Purchase of Electricity Supply Contract in Brazil
Mar 20, 2024
11:00 AM EDT, 03/20/2024 (MT Newswires) -- New Fortress Energy ( NFE ) said Wednesday it has completed its acquisition of a 1.6-gigawatt capacity reserve electricity contract from a portfolio company of private equity firm Denham Capital. Under terms of the purchase agreement, New Fortress will issue a undisclosed amount of its series A convertible preferred stock to Denham Capital...
Celularity Seeks FDA Orphan Drug Status for PDA-002 in Facioscapulohumeral Muscular Dystrophy
Celularity Seeks FDA Orphan Drug Status for PDA-002 in Facioscapulohumeral Muscular Dystrophy
Mar 20, 2024
11:01 AM EDT, 03/20/2024 (MT Newswires) -- Celularity ( CELU ) said Wednesday it submitted an application to the US Food and Drug Administration requesting an orphan drug designation for PDA-002 as a treatment for genetic muscle disorder facioscapulohumeral muscular dystrophy. The FDA has already approved the investigative new drug application for PDA-002 and Celularity ( CELU ) will start...
AAR Signs Multiyear Deal to Supply CFM56-5B Engine Surplus Material to Cebu Pacific
AAR Signs Multiyear Deal to Supply CFM56-5B Engine Surplus Material to Cebu Pacific
Mar 20, 2024
10:59 AM EDT, 03/20/2024 (MT Newswires) -- AAR (AIR) said Wednesday it has a multiyear agreement to provide surplus material for the CFM56-5B engine to Cebu Pacific. Financial details weren't disclosed. Under the accord, AAR said it will assist with the 30 scheduled shop visits for CFM56-5B engines that Cebu Pacific has scheduled throughout the contract period. Shares of ARR...
Copyright 2023-2026 - www.financetom.com All Rights Reserved